Life expectancy of HIV-positive adults: A review

Sexual Health

Volumn 8, Issue 4, 2011, Pages 526-533

  May, Margaret T ^a   Ingle, Suzanne M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

aging; antiretroviral therapy; CD4; immunosuppression; prognosis; sociodemographics.

Indexed keywords

ANTIRETROVIRUS AGENT;

AGING; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DEMOGRAPHY; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MORTALITY; PROGNOSIS; REVIEW; SEX DIFFERENCE; SURVIVAL TIME; VIRUS TRANSMISSION;

AGED; AGED, 80 AND OVER; AGING; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; DELAYED DIAGNOSIS; DISEASE MANAGEMENT; EARLY DIAGNOSIS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; LIFE EXPECTANCY; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 81055144398     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH11046     Document Type: Review

References (56)

1. World Health Organization (WHO).Global health indicators: Part 2.Geneva: WHO; 2008.Available online at: http://www.who.int/ whosis/whostat/EN-WHS08- Table4-HSR.pdf [verified February 2011].
2. Zwahlen M, Harris RJ, Hogg R, Costagliola D, May M, de Wolf F, et al.Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in eight industrialized countries.Int J Epidemiol 2009; 38: 1624-33
3. Cooper DA.Life and death in the cART era.Lancet 2008; 372: 266-7.doi:10.1016/S0140-6736(08)61086-7 (Pubitemid 352020419)
4. Lohse N, Hansen AB, Gerstoft J, Obel N.Improved survival in HIV-infected persons: consequences and perspectives.J Antimicrob Chemother 2007; 60: 461-3.doi:10.1093/jac/dkm241 (Pubitemid 47303950)
5. Santrock J.A topical approach to life-span development.New York: McGraw-Hill; 2007.
6. Braitstein P, Brinkhof MW, Dabis F, SchechterM, Boulle A, Miotti P, et al.Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and highincome countries.Lancet 2006; 367: 817-24.doi:10.1016/S0140- 6736(06)68337-2
7. United Nations (UN).World population prospects, the 2010 Revision.New York: UN; 2008.Available online at: http://esa.un.org/unpd/ wpp/Excel-Data/ mortality.htm [verified February 2011].
8. Chigwedere P, Seage GR III, Gruskin S, Lee TH.Estimating the lost benefits of antiretroviral drug use in South Africa.J Acquir Immune Defic Syndr 2008; 49: 410-5.doi:10.1097/QAI.0b013e31818a6cd5
9. Mahy M, Stover J, Stanecki K, Stoneburner R, Tassie JM.Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults.Sex Transm Infect 2010; 86: ii67-71.doi:10.1136/sti.2010. 046060
10. ART-CC Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet 2008; 372: 293-9.doi:10.1016/S0140-6736(08) 61113-7
11. Gardner JW, Sanborn JS.Years of potential life lost (YPLL) - what does it measure? Epidemiology 1990; 1: 322-9.doi:10.1097/ 00001648-199007000-00012 (Pubitemid 20304823)
12. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al.The survival benefits of AIDS treatment in the United States.J Infect Dis 2006; 194: 11-9.doi:10.1086/505147
13. UNAIDS.reference group on estimates map.Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: recommendations of the UNAIDS reference group on estimates, modelling and projections.AIDS 2002; 16: W1-14.
14. Bulatao R.Population and mortality after AIDS.In: Jamison D, Feachem R, Makgoba M, editors.Disease and mortality in sub- Saharan Africa, 2nd edn.Washington, DC: World Bank; 2006.Available online at: http://www.ncbi.nlm. nih.gov/books/NBK2299/ [verified July 2011].
15. Koblin BA, Hessol NA, Zauber AG, Taylor PE, Buchbinder SP, Katz MH, et al.Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990.Am J Epidemiol 1996; 144: 916-23. (Pubitemid 26383172)
16. Babiker A, Darby S, De Angelis D, Kwart D, Porter K, Beral V, et al.Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis.Lancet 2000; 355: 1131-7.doi:10.1016/ S0140-6736(00)02061-4 (Pubitemid 30172934)
17. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al.Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.Lancet 2005; 366: 378-84.doi:10.1016/ S0140-6736(05)67022-5 (Pubitemid 41073955)
18. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al.Changing patterns of mortality across Europe in patients infected with HIV-1.EuroSIDA Study Group.Lancet 1998; 352: 1725-30.doi:10.1016/S0140-6736(98) 03201-2 (Pubitemid 28534954)
19. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al.Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.JAMA 1998; 279: 450-4.doi:10.1001/jama.279.6.450 (Pubitemid 28082255)
20. Blower SM, Gershengorn HB, Grant RM.A tale of two futures: HIV and antiretroviral therapy in San Francisco.Science 2000; 287: 650-4.doi:10.1126/ science.287.5453.650 (Pubitemid 30070912)
21. Wood E, Low-Beer S, Bartholomew K, Landolt M, Oram D, O'Shaughnessy MV, et al.Modern antiretroviral therapy improves life expectancy of gay and bisexual males in Vancouver's West End.Can J Public Health 2000; 91: 125-8. (Pubitemid 30364800)
22. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al.Survival of persons with and without HIV infection in Denmark, 1995-2005.Ann Intern Med 2007; 146: 87-95. (Pubitemid 351640011)
23. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F.Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.AIDS 2010; 24: 1527-35.doi:10.1097/QAD.0b013e32833a3946
24. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, et al.Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.Clin Infect Dis 2009; 49: 1570-8.doi:10.1086/ 644772
25. Harrison KM, Song R, Zhang X.Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States.J Acquir Immune Defic Syndr 2010; 53: 124-30.doi:10.1097/ QAI.0b013e3181b563e7
26. May M, Gompels M, Sabin C.Impact on life expectancy of late diagnosis and treatment of HIV-1 infected individuals: UK CHIC.Tenth International Congress on Drug Therapy in HIV Infection; 2010; Nov 7-11; Glasgow, UK.
27. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, et al.The British Diabetic Association cohort study I: all-cause mortality in patients with insulin-treated diabetes mellitus.Diabet Med 1999; 16: 459-65.doi:10.1046/j.1464-5491.1999.00075.x
28. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, et al.Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.HIV Med 2010; 11: 432-8.
29. Lampe FC, Smith CJ, Madge S, Kinloch-de LS, Tyrer M, Sabin CA, et al.Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004.Arch Intern Med 2007; 167: 692-700.doi:10.1001/ archinte.167.7.692 (Pubitemid 46598462)
30. Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, et al.Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008; 22: 349-56.doi:10.1097/QAD. 0b013e3282f4709a
31. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, et al.Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.Ann Intern Med 2008; 149: 289-99.
32. Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, et al.Stability of antiretroviral regimens in patients with viral suppression.AIDS 2008; 22: 1039-46.doi:10.1097/QAD.0b013e3 282fec415 (Pubitemid 351769742)
33. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters.Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.AIDS 2007; 21: 1035-9.doi:10.1097/QAD.0b013e32 0b 07761
34. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, et al.Increased regimen durability in the era of oncedaily fixed-dose combination antiretroviral therapy.AIDS 2008; 22: 1951-60.doi:10.1097/QAD.0b013e32830efd79
35. Kitahata MM, Van Rompaey SE, Dillingham PW, Koepsell TD, Deyo RA, Dodge W, et al.Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS.J Gen Intern Med 2003; 18: 95-103.doi:10.1046/j.1525- 1497.2003.11049.x (Pubitemid 36278945)
36. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG.The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004).AIDS 2006; 20: 2371-9.doi:10.1097/QAD.0b013e32801138f7 (Pubitemid 44789540)
37. Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, et al.Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.HIV Med 2008; 9: 47-56.doi:10.1111/j.1468- 1293.2008.00512.x
38. Scherrer A, Ledergerber B, von Wyl V, Boni J, Burgisser P, Yerly S, et al.Effect of HIV-1 subtype on virologic outcomes in Caucasian patients receiving cART in Switzerland.18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27; Boston, USA.
39. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al.Gender and the use of antiretroviral treatment in resourceconstrained settings: findings from a multicenter collaboration.J Womens Health (Larchmt) 2008; 17: 47-55.doi:10.1089/jwh.2007.0353 (Pubitemid 351197536)
40. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al.British HIV Association guidelines for the treatment of HIV-1- infected adults with antiretroviral therapy 2008.HIV Med 2008; 9: 563-608.doi:10.1111/j. 1468-1293.2008.00636.x
41. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.HIV Med 2003; 4: 1-41.doi:10.1046/j.1468- 1293.4.s1.3.x (Pubitemid 37304366)
42. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK.Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.Ann Intern Med 2002; 137: 381-433.
43. Panel on Antiretroviral Guidelines for Adults and Adolescents (PAGAA).Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents.Department of Health and Human Services USA; January 10, 2011; 1-166.Available online at: http:// aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf [verified May 2011].
44. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, et al.Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update.Curr Opin HIV AIDS 2010; 5: 298-304.
45. World Health Organization (WHO).Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach.Geneva: WHO; 2004.Available online at: http://www.who.int/hiv/pub/prev- care/en/arvrevision2003en.pdf [verified May 2011].
46. World Health Organization (WHO).Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.Geneva: WHO; 2010.Available online at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf [verified May 2011].
47. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al.Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Lancet 2002; 360: 119-29.doi:10.1016/S0140-6736(02) 09411-4 (Pubitemid 34786200)
48. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al.Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.AIDS 2007; 21: 1185-97.doi:10.1097/QAD.0b013e328133f285 (Pubitemid 46763289)
49. Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G, et al.Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.AIDS 2009; 23: 2199-208.doi:10.1097/QAD.0b013e3283305a00
50. Lewden C, The Mortality Working Group of COHERE.Time with CD4 cell count above 500 cells/mm3 allows HIV-infected men, but not women, to reach similar mortality rates to those of the general population: a 7-year analysis.17th Conference on Retroviruses and Infections; 2010 Feb 16-19; San Francisco, USA.
51. ART-CC Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies.Clin Infect Dis 2010; 50: 1387-96.doi:10.1086/ 652283
52. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al.Changes in the risk of death after HIV seroconversion compared with mortality in the general population.JAMA 2008; 300: 51-9.doi:10.1001/jama.300.1.51 (Pubitemid 351920404)
53. Powderley W.Growing old with HIV - dealing with co-morbidities.10th International Congress on Drug Therapy in HIV Infection; 2010 Nov 7; Glasgow, UK.
54. Back D.HIV therapy in an ageing population - the challenge of polypharmacy.10th International Congress on Drug Therapy in HIV Infection; 2010 Nov 7; Glasgow, UK.
55. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al.Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.Antivir Ther 2010; 15: 413-23.doi:10.3851/IMP1540
56. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al.Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society - USA panel.JAMA 2010; 304: 321-33.doi:10.1001/jama. 2010.1004